Physiomics PLC IMC Presentation on Board Changes
23 Janeiro 2024 - 4:00AM
RNS Non-Regulatory
TIDMPYC
Physiomics PLC
23 January 2024
23 January 2024
Physiomics plc
("Physiomics" or "the Company")
IMC Presentation on Board Changes
Physiomics plc (AIM: PYC), the oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions, will provide a brief
update on the Board changes via Investor Meet Company on 29 January
2024 at 1:00 pm GMT. During this presentation, Jim Millen CEO and
Peter Sargent would be happy to take questions relating to the
changes announced yesterday.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9:00 am GMT the working
day before the meeting or at any time during the live
presentation.
Investors can sign up to Investor Meet Company for free and add
to meet Physiomics plc via:
https://www.investormeetcompany.com/physiomics-plc/register-investor
. Investors who already follow the Company on the Investor Meet
Company platform will automatically be invited.
Enquiries:
Physiomics plc
Dr Jim Millen, Non-Executive Chairman, +44 (0)1865 784 980
Dr Peter Sargent, Chief Executive Officer, +44 (0)1865 784
980
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions. The Company's Virtual
Tumour(TM) technology uses computer modelling to predict the
effects of cancer drugs and treatments to improve the success rate
of drug discovery and development projects while reducing time and
cost. The predictive capability of Physiomics' technologies have
been confirmed by over 100 projects, involving over 50 targets and
75 drugs, and has worked with clients such as Merck KGaA, Astellas,
Merck & Co and Bicycle Therapeutics.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAZZGZMDZDGDZM
(END) Dow Jones Newswires
January 23, 2024 02:00 ET (07:00 GMT)
Physiomics (LSE:PYC)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Physiomics (LSE:PYC)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024